In brief: Starpharma, Proteome Systems, Meditech, C3, Biodiem
Thursday, 31 March, 2005
Starpharma (ASX: SPL, USOTC:SPHRY) has appointed former Cerylid Biosciences chief executive officer Dr Jackie Fairley to the newly created position of chief operating officer. Fairley will begin her role with Starpharma toward the middle of 2005.
Proteome Systems (ASX:PXL) has appointed Dr Arthur Emmett as a non-executive director. Dr Emmett has worked for 30 years in the pharmaceutical industry, including stints at G.D. Searle, Parke Davis., W.S. Merrell, Ciba Geigy (now Novartis). Since 1997 he has assisted European pharmaceutical companies with their China business strategies.
Management consultant Robert Stewart has joined the board of Meditech Research (ASX: MTR) as a non-executive director and chairman designate. Stewart was formerly the national managing partner of law firm Minter Ellison, and is currently chairman of Melbourne IT, Plantic and CE Bartlett.
Clinical Cell Culture (C3, ASX: CCE) has appointed its chief executive officer Troels Jordansen as an executive director of the company.
Dr Peter Hodsman has replaced Prof Robert Borland as research and development director of Melbourne flu vaccine company Biodiem (ASX:BDM). Dr Hodsman was a consultant physician and National Heart Foundation and senior research fellow in the department of medicine at the Austin Hospital, before working at Glaxo Australia, Aventis and Abbott Laboratories.
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
